These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 20535065)

  • 1. Compulsive singing associated with a dopamine agonist in Parkinson disease.
    Kataoka H; Ueno S
    Cogn Behav Neurol; 2010 Jun; 23(2):140-1. PubMed ID: 20535065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compulsive eating and weight gain related to dopamine agonist use.
    Nirenberg MJ; Waters C
    Mov Disord; 2006 Apr; 21(4):524-9. PubMed ID: 16261618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
    Kimber TE; Thompson PD; Kiley MA
    J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multiple latency test in a patient with episodes of sleep induced by pergolide].
    Jiménez-Jiménez FJ; Velasco I; de Toledo M; Sayed Y; Zurdo J; Ortí-Pareja M
    Rev Neurol; 2002 Jun 16-30; 34(12):1140-1. PubMed ID: 12134281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies.
    Hassan A; Bower JH; Kumar N; Matsumoto JY; Fealey RD; Josephs KA; Ahlskog JE
    Parkinsonism Relat Disord; 2011 May; 17(4):260-4. PubMed ID: 21310646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy.
    Comella CL; Morrissey M; Janko K
    Neurology; 2005 Apr; 64(8):1450-1. PubMed ID: 15851743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
    van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists.
    Singh A; Kandimala G; Dewey RB; O'Suilleabhain P
    J Clin Neurosci; 2007 Dec; 14(12):1178-81. PubMed ID: 17720504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hiccups associated with dopamine agonists in Parkinson disease.
    Sharma P; Morgan JC; Sethi KD
    Neurology; 2006 Mar; 66(5):774. PubMed ID: 16534128
    [No Abstract]   [Full Text] [Related]  

  • 11. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Punding in patients on dopamine agonists for restless leg syndrome.
    Evans AH; Stegeman JR
    Mov Disord; 2009 Jan; 24(1):140-1. PubMed ID: 18855926
    [No Abstract]   [Full Text] [Related]  

  • 13. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
    Roth J; Ulmanová O; Růzicka E
    Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
    McKeon A; Josephs KA; Klos KJ; Hecksel K; Bower JH; Michael Bostwick J; Eric Ahlskog J
    Parkinsonism Relat Disord; 2007 Dec; 13(8):516-9. PubMed ID: 17544807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].
    van Laar T; Berendse H; Bloem BR; Boon AJ; van Hilten JJ; Hovestadt A; de Koning-Tijssen MA; Nijssen PC; Weber WE
    Ned Tijdschr Geneeskd; 2009 Jan; 153(3):87-90. PubMed ID: 19235345
    [No Abstract]   [Full Text] [Related]  

  • 17. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine agonists and valvular heart disease.
    Linkova H; Ruzicka E; Penicka M
    N Engl J Med; 2007 Apr; 356(16):1676; author reply 1678-80. PubMed ID: 17447279
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pleural effusion caused by pergolide].
    Salvadó M; Barreiro B; González C
    Arch Bronconeumol; 2009 Jan; 45(1):62-3. PubMed ID: 19186303
    [No Abstract]   [Full Text] [Related]  

  • 20. [Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].
    Sánchez-Chapado M; Angulo Cuesta J; Guil Cid M; Jiménez FJ; López Alvarez YJ
    Arch Esp Urol; 1995 Dec; 48(10):979-83. PubMed ID: 8588730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.